newsfilter
← Latest News
GlobeNewswire·

TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years

COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults